海外の治験の状況「1」での検索結果
1993件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Plasma Pharmacokinetics study of CD5024 1% cream in subjects with papulopustular rosacea
- PAPULOPUSTULAR ROSACEA MedDRA version: 9.1 Level: LLT Classification code 10039218 Term: Rosacea
- France, Germany, Hungary
- 2008-05-19
Authorised
- A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to less than 6 Years Old) Subjects with Congenital FXIII A-subunit Deficiency
- Congenital FXIII A-subunit Deficiency MedDRA version: 13.1 Level: PT Classification code 10016083 Term: Factor XIII deficiency System Organ Class: 10010331 - Congenital, familial and genetic disorders
- United Kingdom
- 2010-07-07
Authorised
- Incretin-based therapy in preclinical type 1 diabetes in adults.
- Type 1 diabetes MedDRA version: 18.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Finland
- 2015-11-05
Authorised
- Imaging with a radioactively-labeled antibody against PDL-1 in patients with lymphoma
- Diffuse large B-cell Lymphoma MedDRA version: 20.0 Level: HLT Classification code 10012819 Term: Diffuse large B-cell lymphomas System Organ Class: 100000004851 MedDRA version: 20.0 Level: PT Classification code 10012818 Term: Diffuse large B-cell lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10012820 Term: Diffuse large B-cell lymphoma NOS System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Netherlands
- 2018-09-26
Authorised
- Liraglutide in type 1 diabetes - A randomised, double-blind, placebo-controlled, parallel group, multi-centre trial of 242 liraglutide treatment in subjects with newly-diagnosed type 1 diabetes (The NewLira Study)
- The effect of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment. Also to investigate the effect on postprandial glucagon levels following sustacal meal test, HbA1c, insulin dose, self-monitored blood glucose profile,frequency of hypoglycaemic events, fasting and postprandial cholesterol profile, weight, waist circumference and quality of life. . MedDRA version: 16.1 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Denmark
- 2013-01-17
Authorised
- Empagliflozin as Adjunctive to inSulin thErapy in Type 1 diabetes over 52 weeks (EASE-2)
- Type 1 diabetes mellitus br>MedDRA version: 19.1 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
- Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Netherlands, Norway, Poland, Spain, Sweden, Taiwan, United Kingdom, United States
- 2015-04-02
Authorised
- The comparison of the number of insulin-producing cells during and shortly after the honeymoon phase of type 1 diabetes
- Type 1 diabetes MedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
- Netherlands
- 2017-11-13
Authorised
- A Study to Assess the Long-term Safety of Rechon Insulin Human Soluble in Type 1 Diabetic Patients.
- Type 1 Diabetes MedDRA version: 20.0 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Germany, Poland
- 2017-08-29
Authorised
- Fibrinogen (blood protein) supplementation in patients that have developed fibrinogen deficiency during surgery.
- The sequence of events culminating in Pseudomyxoma peritonei (PMP) is thought to involve growth of an appendiceal adenoma with distension of the appendix by mucus and mucinous tumour cells. The appendix eventually ruptures. Patients undergoing the PMP surgery develop a coagulopathy predominantly characterised by reduced levels of fibrinogen, resulting in reduced whole blood clot firmness. MedDRA version: 20.0 Level: PT Classification code 10037138 Term: Pseudomyxoma peritonei System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
- United Kingdom
- 2018-06-29
Authorised
- Long term subcutaneous tinzaparin compared with tinzaparin and oral anticoagulants in the treatment of acute pulmonary embolism. A multicentre, prospective, randomised, open, parallel group clinical trial.
- Patients with clinical suspicion of Pulmonar Thromboembolism confirmed according to the PIOPED criteria. MedDRA version: 4.0 Level: PT Classification code 10037377
- Spain
- 2005-12-01